Medicine: Panizumatoseusupplement therapy can improve the objective response of colorectal cancer patients with WT KRAS to some extent, but it can increase the incidence of adverse events.

The efficacy of panitore supplementation treatment for colorectal cancer remains controversial.
we conduct a systematic review and meta-analysis to explore the effects of panizumap supplements on the effectiveness of colorectal cancer treatment.
we searched the PubMed, EMbase, Web of Science, EBSCO and Cochrane Library databases through June 2019 to evaluate the efficacy of panizumab supplementation treatment for colorectal cancer in a randomized controlled trial (RCTs).
the meta-analysis is carried out using a random effect model.
results, 5 RCTs were included in the meta-analysis.
overall, panizumab supplements were associated with an increase in objective responses to wild -type (WT) KRAS compared to the colorectal cancer control group (RR s 1.70; 95% CI s 1.07-2.69; P s .03), but the objective response to mutant KRAS (RR s.0. 92;95% CI s 0.79-1.08; P - .32), objective response (RR s 1.35; 95% CI s 1.00-1.83; P - 0.05), WT KRAS progression (RR s 0.94; 95% CI s 0. 85-1.02; P - .15), mortality (RR s 0.86; 95% CI - 0.69-1.08; P - .20), or the mortality rate of KRAWTS (RR - 0.94; 95% CI - 0.84-1.05; P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
in addition, the level 3 and 4 adverse events in the Pani mono-resist group were higher than those of the control group (RR s 1.17; 95% CI s 1.08-1.27; P s .0001).
, the results show that panizumatoscopy supplementation therapy can improve the objective response of colorectal cancer patients with WT KRAS, but will lead to an increase in level 3 and 4 adverse events.
.